The Distinguished Career Of Mikhail Blagosklonny

Mikhail Blagosklonny is a cancer and aging scientist. He is a professor of Oncology at the esteemed Roswell Park Cancer Center in Buffalo, New York. Roswell Park is one the institutions that offer comprehensive cancer treatment. Mikhail pursued his medical studies at the prestigious First Pavlov Medical University in Russia. He also earned his PhD in experimentation medicine from the same institution. Later, he moved and settled in the United States. Previously, Mikhail taught at the New York Medical College in Valhalla. He also worked for Ordway Research Institute in Albany as a senior scientist. View Mikhail’s profile on Loop

Blagosklonny has a distinguished career in the field of oncology. Over the years, he has been researching about therapies for aging and cancer. Mikhail has developed a keen interest in finding cures that can kill infected cancer cells without interfering with the normal cells. One of his research zeroed in on the possible role of TOR signaling in cancer and aging. He is one of the proponents of Rapamycin, a drug that is capable of treating cancer. Rapamycin inhibits MTOR. This way, it prolongs the life span of an individual. In cancer, over-activation of MTOR signaling enhances the initiation and development of tumors. Mikhail found out that MTOR activity is deregulated in many types of cancer. Rapamycin was found to increase lifespan in mice. Mikhail believes that cancer patients should use that the drug to prolong their lives as it destroys cancer cells. Mikhail Blagosklonny is the brain behind the aging hyper-function theory that focuses on chemotherapeutic engineering. He has published over 270 papers in peer-reviewed journals, with more than 25,000 citations. Mikhail is the editor-in-chief of various widely read journals, including Cell Cycle, Oncotarget, Aging and Oncoscience. In addition, he works as an associate editor for Cancer Biology & Therapy. Mikhail has seen providing Cell Death & Differentiation with innovative ideas by virtue of sitting on its editorial board. His involvement in the field of cancer and aging has made him one of the renowned oncology scientists in the world. Over the years, he has exhibited a strong love for humanity and a deep vision to create a world free of diseases. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

Oncotarget Rapidly Shares Scientific Findings to Help Researchers as Quickly as Possible

Oncotarget is a free peer-reviewed international online weekly medical journal with the original intent of sharing findings related to cancer research. But as it was found that the causes and effects of cancer-related illnesses branch out into other areas of medicine, the journal currently accepts papers on the following topics: pharmacology, age-related diseases, immunology, physiology, cell biology, metabolism, neuroscience, cardiology, and endocrinology.

The focus of Oncotarget is to allow scientists in varying medical fields to quickly share information related to cancer, cancer-fighting therapies and improving the quality of life of cancer patients through better management of their treatment. To give examples of the wide-ranging scope of articles printed in Oncotarget, three articles recently published in the journal are 1) Parkinson’s disease: no NOP, new hope, 2) Approaching Alzheimer’s disease from a network level and 3) DJ1 at the interface between neuro-regeneration and cancer.

The journal was first established in 2010 and the current Editors-in-Chief are Mikhail V. Blagosklonny and Andrei V. Gudkov, who are both employed at the Roswell Park Cancer Institute located in Buffalo, New York. One of the most remarkable traits of Oncotarget is that it papers are peer-reviewed prior to publishing to ensure the best information is presented scientists as quickly as possible, hence the weekly publishings by Impact Journals. In fact, part of the mission statement of Oncotarget stated on the website is “to make scientific results rapidly and widely available to maximize the impact of research via insightful review.” Each individual paper published in Oncotarget can be printed and shared with peers. The ultimate goal of Oncotarget is life without disease.